• Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
  • 4-Antibody has a powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets
  • Lead programs target six immune checkpoint molecules
  • Checkpoint antibodies have produced unprecedented results against a variety of cancers affecting a large number of patients
  • Collaborations with the Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center
 
Agenus - mark

At Agenus, we believe the best path for treating disease is through activating our own body’s natural mechanisms.

That’s why for 20 years, we’ve focused on building technologies and a product pipeline aimed at treating cancer and infectious disease by helping the body’s immune system target diseased cells with precision.

  • April 16, 2014

    Agenus to Host Annual Meeting of Stockholders
    Read More

     

  • April 2, 2014

    Update On GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study In Non-Small Cell Lung Cancer
    Read More

     

  • March 26, 2014

    Agenus to Present at the 4th Annual Cancer Immunotherapy Conference
    Read More

     

  • March 20, 2014

    GSK’S MAGE-A3 Cancer Immunotherapeutic Phase 3 Study In Non-small Cell Lung Cancer Misses First Co-primary Endpoints
    Read More

     

  • March 5, 2014

    Agenus To Advance Three Checkpoint Modulator Antibodies Into Development
    Read More

     

  • March 5, 2014

    Agenus Reports Fourth Quarter and Full Year 2013 Financial Results
    Read More

     

  • February 13, 2014

    Agenus Completes Acquisition of 4-Antibody
    Read More